Protective Effects of a Novel Agonist of Galanin Receptors Against Doxorubicin-Induced Cardiotoxicity in Rats

[1]  O. Pisarenko,et al.  Galanin and its N-terminal fragments reduce acute myocardial infarction in rats , 2019, Peptides.

[2]  Kaviyarasi Renu,et al.  Molecular mechanism of doxorubicin‐induced cardiomyopathy – An update , 2018, European journal of pharmacology.

[3]  O. Kunduzova,et al.  Cardioprotective properties of N-terminal galanin fragment (2-15) in experimental ischemia/reperfusion injury , 2017, Oncotarget.

[4]  B. He,et al.  Assessment of Subclinical Doxorubicin-induced Cardiotoxicity in a Rat Model by Speckle-Tracking Imaging , 2017, Arquivos brasileiros de cardiologia.

[5]  O. Kunduzova,et al.  Myocardial protection from ischemia/reperfusion injury by exogenous galanin fragment , 2017, Oncotarget.

[6]  Quanjun Yang,et al.  Protective Effects of Dexrazoxane against Doxorubicin-Induced Cardiotoxicity: A Metabolomic Study , 2017, PloS one.

[7]  Shery Jacob,et al.  A simple practice guide for dose conversion between animals and human , 2016, Journal of basic and clinical pharmacy.

[8]  S. Zervou,et al.  Augmentation of Creatine in the Heart , 2015, Mini reviews in medicinal chemistry.

[9]  Paul A Insel,et al.  Experimental design and analysis and their reporting: new guidance for publication in BJP , 2015, British journal of pharmacology.

[10]  L. Wojnowski,et al.  Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both Topoisomerase II isoforms , 2014, BMC Cancer.

[11]  P. Vejpongsa,et al.  Topoisomerase 2β: A Promising Molecular Target for Primary Prevention of Anthracycline‐Induced Cardiotoxicity , 2013, Clinical pharmacology and therapeutics.

[12]  B. Khandheria,et al.  Cardioncology: state of the heart. , 2013, International journal of cardiology.

[13]  T. Bártfai,et al.  Galanin Receptors and Ligands , 2012, Front. Endocrin..

[14]  E. Yeh,et al.  Identification of the molecular basis of doxorubicin-induced cardiotoxicity , 2012, Nature Medicine.

[15]  G. Hassanzadeh,et al.  The Cardioprotective Effects of an Antiemetic Drug, Tropisetron, on Cardiomyopathy Related to Doxorubicin , 2012, Cardiovascular Toxicology.

[16]  H. Crijns,et al.  Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. , 2012, Journal of molecular and cellular cardiology.

[17]  A. Pieniazek,et al.  Nitroxide pirolin reduces oxidative stress generated by doxorubicin and docetaxel in blood plasma of rats bearing mammary tumor. , 2012, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[18]  Vukosava M Torres,et al.  Doxorubicin-Induced Oxidative Injury of Cardiomyocytes - Do We Have Right Strategies for Prevention? , 2012 .

[19]  P. Turner,et al.  Administration of substances to laboratory animals: routes of administration and factors to consider. , 2011, Journal of the American Association for Laboratory Animal Science : JAALAS.

[20]  T. Park,et al.  Diet-induced obesity regulates the galanin-mediated signaling cascade in the adipose tissue of mice. , 2010, Molecular nutrition & food research.

[21]  T. Bártfai,et al.  Galanin, galanin receptors and drug targets. , 2008, Cellular and molecular life sciences : CMLS.

[22]  R. Margreiter,et al.  Analysis of mitochondrial function in situ in permeabilized muscle fibers, tissues and cells , 2008, Nature Protocols.

[23]  T. Bártfai,et al.  Molecular characterization of the ligand binding site of the human galanin receptor type 2, identifying subtype selective interactions , 2007, Journal of neurochemistry.

[24]  B. Kofler,et al.  The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease. , 2007, Pharmacology & therapeutics.

[25]  A. Geist,et al.  Dexrazoxane prevents doxorubicin‐induced long‐term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats , 2007, British journal of pharmacology.

[26]  D. Hydock,et al.  Doxorubicin cardiotoxicity in the rat: an in vivo characterization. , 2007, Journal of the American Association for Laboratory Animal Science : JAALAS.

[27]  R. Olson,et al.  Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism , 2006, Cancer Chemotherapy and Pharmacology.

[28]  T. Wallimann,et al.  Acute toxicity of doxorubicin on isolated perfused heart: response of kinases regulating energy supply. , 2005, American journal of physiology. Heart and circulatory physiology.

[29]  Z. Díaz-Cabiale,et al.  Role of galanin and galanin(1–15) on central cardiovascular control , 2005, Neuropeptides.

[30]  N. Servant,et al.  Dexrazoxane does not protect against doxorubicin-induced damage in young rats. , 2003, American journal of physiology. Heart and circulatory physiology.

[31]  S. Swain,et al.  Congestive heart failure in patients treated with doxorubicin , 2003, Cancer.

[32]  S. Chow,et al.  Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer , 2003, Anti-cancer drugs.

[33]  T. Hökfelt,et al.  Receptor subtype-specific pronociceptive and analgesic actions of galanin in the spinal cord: Selective actions via GalR1 and GalR2 receptors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[34]  P. Singal,et al.  Effects of probucol on changes of antioxidant enzymes in adriamycin-induced cardiomyopathy in rats. , 2000, Cardiovascular research.

[35]  J. Wojtacki,et al.  Anthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention--review of the literature. , 2000, Medical science monitor : international medical journal of experimental and clinical research.

[36]  H. Allen,et al.  Effects of Doxorubicin on Diastolic Function, Contractile Reserve, and Ventricular–Vascular Coupling in Piglets , 1998, Pediatric Cardiology.

[37]  N. Yanaihara,et al.  Role of N-terminal active sites of galanin in neurally evoked circular muscle contractions in the guinea-pig ileum. , 1997, European journal of pharmacology.

[38]  J. Williams,et al.  Differences in nucleotide compartmentation and energy state in isolated and in situ rat heart: assessment by 31P-NMR spectroscopy. , 1996, Biochimica et biophysica acta.

[39]  J. Glickson,et al.  The relationship between cardiac function and metabolism in acute adriamycin-treated perfused rat hearts studied by 31P and 13C NMR spectroscopy. , 1990, Journal of molecular and cellular cardiology.

[40]  T. Ruigrok,et al.  Effects of the anti-cancer drug adriamycin on the energy metabolism of rat heart as measured by in vivo 31P-NMR and implications for adriamycin-induced cardiotoxicity. , 1987, Biochimica et biophysica acta.

[41]  S. Wallace,et al.  Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. , 1982, Annals of internal medicine.

[42]  T. Bártfai,et al.  Galanin – 25 years with a multitalented neuropeptide , 2008, Cellular and Molecular Life Sciences.

[43]  A. Favier,et al.  Lipid peroxidation products, and vitamin and trace element status in patients with cancer before and after chemotherapy, including adriamycin , 2007, Biological Trace Element Research.

[44]  Y. Kakinuma,et al.  Doxorubicin induces apoptosis by activation of caspase-3 in cultured cardiomyocytes in vitro and rat cardiac ventricles in vivo. , 2006, Journal of pharmacological sciences.